Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 29.32
(1.35%)
USD 29.32
(1.35%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -230.01 Million USD | 42.45% |
| 2022 | -227.75 Million USD | -2571.43% |
| 2021 | -239 Thousand USD | 87.79% |
| 2020 | -107.88 Million USD | -146.99% |
| 2019 | 411.53 Million USD | 694.6% |
| 2018 | -18.83 Million USD | -393.31% |
| 2017 | 39.79 Million USD | 145.31% |
| 2016 | -8.82 Million USD | 16.62% |
| 2015 | -40.93 Million USD | -99.62% |
| 2014 | -22.77 Million USD | 46.14% |
| 2013 | -37.42 Million USD | 0.59% |
| 2012 | -42.68 Million USD | 14.03% |
| 2011 | -56.27 Million USD | -58.94% |
| 2010 | -38.75 Million USD | -38.13% |
| 2009 | -9.79 Million USD | -421.75% |
| 2008 | 4.11 Million USD | 83.75% |
| 2007 | -26.15 Million USD | 49.44% |
| 2006 | -64.23 Million USD | -91.33% |
| 2005 | -42.4 Million USD | 13.4% |
| 2004 | -73.25 Million USD | 41.06% |
| 2003 | -64.92 Million USD | -34.5% |
| 2002 | -40.01 Million USD | -7.5% |
| 2001 | -39.13 Million USD | -712.96% |
| 2000 | -23.45 Million USD | 81.77% |
| 1999 | -37.9 Million USD | -12.87% |
| 1998 | -28.2 Million USD | 16.05% |
| 1997 | -28.1 Million USD | -5.54% |
| 1996 | -26.5 Million USD | -18.99% |
| 1995 | -22.8 Million USD | -7.05% |
| 1994 | -18.6 Million USD | -59.6% |
| 1993 | -15.1 Million USD | 30.41% |
| 1992 | -19.6 Million USD | -90.35% |
| 1991 | -9.6 Million USD | -134.15% |
| 1990 | -4.1 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -143.86 Million USD | -556.76% |
| 2024 Q2 | -60.51 Million USD | 67.09% |
| 2023 Q3 | -123 Million USD | -108.47% |
| 2023 Q4 | -1.67 Million USD | 98.64% |
| 2023 FY | - USD | 42.45% |
| 2023 Q1 | -97 Million USD | 72.91% |
| 2023 Q2 | -59 Million USD | 39.18% |
| 2022 Q1 | -53.74 Million USD | -124.32% |
| 2022 Q2 | -94.05 Million USD | -75.01% |
| 2022 Q3 | -50.68 Million USD | 46.11% |
| 2022 Q4 | -358 Million USD | -606.32% |
| 2022 FY | - USD | -2571.43% |
| 2021 FY | - USD | 87.79% |
| 2021 Q1 | -83.92 Million USD | -264.9% |
| 2021 Q2 | -56.74 Million USD | 32.39% |
| 2021 Q4 | 221 Million USD | 374.16% |
| 2021 Q3 | -80.61 Million USD | -42.06% |
| 2020 Q1 | -57.11 Million USD | -121.88% |
| 2020 FY | - USD | -146.99% |
| 2020 Q2 | -47.87 Million USD | 16.18% |
| 2020 Q3 | -31.95 Million USD | 33.24% |
| 2020 Q4 | -23 Million USD | 28.03% |
| 2019 FY | - USD | 694.6% |
| 2019 Q1 | 124.93 Million USD | 1062.69% |
| 2019 Q3 | 6.06 Million USD | 131.92% |
| 2019 Q2 | -19 Million USD | -115.21% |
| 2019 Q4 | 261 Million USD | 4204.09% |
| 2018 Q2 | -47.28 Million USD | -1263.19% |
| 2018 Q4 | 10.74 Million USD | 170.04% |
| 2018 FY | - USD | -393.31% |
| 2018 Q3 | -15.34 Million USD | 67.56% |
| 2018 Q1 | -3.46 Million USD | -104.9% |
| 2017 FY | - USD | 145.31% |
| 2017 Q1 | 14.92 Million USD | -63.74% |
| 2017 Q4 | -1.69 Million USD | -111.81% |
| 2017 Q3 | 14.33 Million USD | 957.57% |
| 2017 Q2 | -1.67 Million USD | -111.2% |
| 2016 Q4 | 41.15 Million USD | 123.89% |
| 2016 Q2 | -46.65 Million USD | 14.63% |
| 2016 Q3 | 18.38 Million USD | 139.4% |
| 2016 FY | - USD | 16.62% |
| 2016 Q1 | -54.65 Million USD | 11.77% |
| 2015 Q4 | -61.94 Million USD | -144.72% |
| 2015 Q1 | -6.97 Million USD | -123.7% |
| 2015 Q2 | 44.64 Million USD | 739.81% |
| 2015 Q3 | -25.31 Million USD | -156.69% |
| 2015 FY | - USD | -99.62% |
| 2014 Q2 | -4.32 Million USD | 84.22% |
| 2014 FY | - USD | 46.14% |
| 2014 Q4 | 29.44 Million USD | 254.38% |
| 2014 Q1 | -27.37 Million USD | -37.84% |
| 2014 Q3 | -19.07 Million USD | -341.53% |
| 2013 Q3 | -25.5 Million USD | -221.71% |
| 2013 FY | - USD | 0.59% |
| 2013 Q4 | -19.85 Million USD | 22.14% |
| 2013 Q2 | -7.92 Million USD | -587.88% |
| 2013 Q1 | 1.62 Million USD | 120.24% |
| 2012 Q3 | -27.63 Million USD | -789.23% |
| 2012 Q1 | -18.83 Million USD | 2.82% |
| 2012 Q4 | -8.03 Million USD | 70.95% |
| 2012 FY | - USD | 14.03% |
| 2012 Q2 | 4.01 Million USD | 121.29% |
| 2011 Q4 | -19.37 Million USD | 14.65% |
| 2011 FY | - USD | -58.94% |
| 2011 Q1 | -16.25 Million USD | -94.53% |
| 2011 Q2 | -15.09 Million USD | 7.17% |
| 2011 Q3 | -22.7 Million USD | -50.41% |
| 2010 FY | - USD | -38.13% |
| 2010 Q4 | -8.35 Million USD | 15.38% |
| 2010 Q2 | -22.61 Million USD | -255.23% |
| 2010 Q1 | -6.36 Million USD | 45.45% |
| 2010 Q3 | -9.87 Million USD | 56.32% |
| 2009 FY | - USD | -421.75% |
| 2009 Q3 | -10.39 Million USD | -115.37% |
| 2009 Q2 | -4.82 Million USD | -651.87% |
| 2009 Q4 | -11.67 Million USD | -12.26% |
| 2009 Q1 | -642 Thousand USD | -119.89% |
| 2008 Q2 | -4.88 Million USD | 64.54% |
| 2008 Q4 | 3.22 Million USD | 174.65% |
| 2008 FY | - USD | 83.75% |
| 2008 Q1 | -13.78 Million USD | -63.3% |
| 2008 Q3 | -4.32 Million USD | 11.56% |
| 2007 Q3 | 10.05 Million USD | 151.17% |
| 2007 FY | - USD | 49.44% |
| 2007 Q1 | -21.2 Million USD | -62.39% |
| 2007 Q2 | -19.65 Million USD | 7.3% |
| 2007 Q4 | -8.44 Million USD | -183.95% |
| 2006 FY | - USD | -91.33% |
| 2006 Q4 | -13.05 Million USD | 36.32% |
| 2006 Q3 | -20.5 Million USD | -3.58% |
| 2006 Q2 | -19.79 Million USD | -24.15% |
| 2006 Q1 | -15.94 Million USD | -116.54% |
| 2005 Q3 | -14.08 Million USD | -21.16% |
| 2005 Q4 | -7.36 Million USD | 47.72% |
| 2005 Q2 | -11.62 Million USD | -24.46% |
| 2005 FY | - USD | 13.4% |
| 2005 Q1 | -9.33 Million USD | -174.16% |
| 2004 FY | - USD | 41.06% |
| 2004 Q1 | -22.33 Million USD | 1.17% |
| 2004 Q2 | -21.34 Million USD | 4.45% |
| 2004 Q3 | -17.88 Million USD | 16.19% |
| 2004 Q4 | 12.59 Million USD | 170.41% |
| 2003 Q4 | -21.48 Million USD | -11.64% |
| 2003 Q2 | -15.91 Million USD | 3.4% |
| 2003 FY | - USD | -34.5% |
| 2003 Q1 | -18.91 Million USD | 2.88% |
| 2003 Q3 | -19.06 Million USD | -27.21% |
| 2002 Q1 | -9.71 Million USD | -26.26% |
| 2002 Q4 | -16.96 Million USD | 24.56% |
| 2002 Q3 | -17.5 Million USD | -123.84% |
| 2002 Q2 | -12.33 Million USD | -3.36% |
| 2002 FY | - USD | -7.5% |
| 2001 FY | - USD | -712.96% |
| 2001 Q1 | -17.23 Million USD | -182.71% |
| 2001 Q4 | -7.69 Million USD | -63.52% |
| 2001 Q3 | -4.7 Million USD | 71.41% |
| 2001 Q2 | -16.46 Million USD | 4.47% |
| 2000 Q4 | -6.09 Million USD | -236.93% |
| 2000 Q1 | -5.9 Million USD | 38.48% |
| 2000 Q3 | 206 Thousand USD | 224.32% |
| 2000 Q2 | -3.58 Million USD | 39.37% |
| 2000 FY | - USD | 81.77% |
| 1999 Q3 | -6.1 Million USD | 40.78% |
| 1999 FY | - USD | -12.87% |
| 1999 Q4 | -9.6 Million USD | -57.38% |
| 1999 Q1 | -11.2 Million USD | -103.64% |
| 1999 Q2 | -10.3 Million USD | 8.04% |
| 1998 Q3 | -1 Million USD | 92.96% |
| 1998 Q4 | -5.5 Million USD | -450.0% |
| 1998 Q2 | -14.2 Million USD | -17.36% |
| 1998 Q1 | -12.1 Million USD | -2.54% |
| 1998 FY | - USD | 16.05% |
| 1997 FY | - USD | -5.54% |
| 1997 Q2 | -10.5 Million USD | -7.14% |
| 1997 Q3 | -3.7 Million USD | 64.76% |
| 1997 Q1 | -9.8 Million USD | 16.24% |
| 1997 Q4 | -11.8 Million USD | -218.92% |
| 1996 Q4 | -11.7 Million USD | -53.95% |
| 1996 Q1 | -4.8 Million USD | 35.14% |
| 1996 FY | - USD | -18.99% |
| 1996 Q3 | -7.6 Million USD | 16.48% |
| 1996 Q2 | -9.1 Million USD | -89.58% |
| 1995 Q3 | -8.2 Million USD | -26.15% |
| 1995 Q4 | -7.4 Million USD | 9.76% |
| 1995 FY | - USD | -7.05% |
| 1995 Q2 | -6.5 Million USD | 1.52% |
| 1995 Q1 | -6.6 Million USD | 41.07% |
| 1994 Q2 | -4.8 Million USD | 37.66% |
| 1994 Q3 | -5 Million USD | -4.17% |
| 1994 Q4 | -11.2 Million USD | -124.0% |
| 1994 FY | - USD | -59.6% |
| 1994 Q1 | -7.7 Million USD | -75.0% |
| 1993 Q2 | -4.6 Million USD | 9.8% |
| 1993 Q4 | -4.4 Million USD | 0.0% |
| 1993 FY | - USD | 30.41% |
| 1993 Q1 | -5.1 Million USD | 25.0% |
| 1993 Q3 | -4.4 Million USD | 4.35% |
| 1992 FY | - USD | -90.35% |
| 1992 Q2 | -3.7 Million USD | 21.28% |
| 1992 Q1 | -4.7 Million USD | 2.08% |
| 1992 Q3 | -4.3 Million USD | -16.22% |
| 1992 Q4 | -6.8 Million USD | -58.14% |
| 1991 Q2 | -2.1 Million USD | -71.43% |
| 1991 Q3 | -2 Million USD | 16.67% |
| 1991 Q4 | -4.8 Million USD | -140.0% |
| 1991 FY | - USD | -178.05% |
| 1991 Q1 | -1.2 Million USD | 76.67% |
| 1990 Q3 | 500 Thousand USD | 0.0% |
| 1990 Q4 | -6 Million USD | -1300.0% |
| 1990 Q1 | 500 Thousand USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| 1990 Q2 | 500 Thousand USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Atara Biotherapeutics, Inc. | -265.99 Million USD | 13.529% |
| Cara Therapeutics, Inc. | -117.65 Million USD | -95.504% |
| Editas Medicine, Inc. | -163.11 Million USD | -41.009% |
| Heron Therapeutics, Inc. | -103.79 Million USD | -121.607% |
| Iovance Biotherapeutics, Inc. | -449.01 Million USD | 48.774% |
| Walgreens Boots Alliance, Inc. | -11.27 Billion USD | 97.961% |
| uniQure N.V. | -253.1 Million USD | 9.123% |
| Aclaris Therapeutics, Inc. | -87.98 Million USD | -161.42% |
| Agios Pharmaceuticals, Inc. | -345.46 Million USD | 33.42% |
| Amicus Therapeutics, Inc. | -92.07 Million USD | -149.796% |
| bluebird bio, Inc. | -167.16 Million USD | -37.598% |
| Blueprint Medicines Corporation | -474.61 Million USD | 51.537% |
| Adicet Bio, Inc. | -136.53 Million USD | -68.462% |
| Dynavax Technologies Corporation | 9.66 Million USD | 2479.578% |
| IQVIA Holdings Inc. | 3.25 Billion USD | 107.064% |
| Myriad Genetics, Inc. | -67.8 Million USD | -239.248% |
| Neurocrine Biosciences, Inc. | 416.1 Million USD | 155.278% |
| Sarepta Therapeutics, Inc. | -439.19 Million USD | 47.629% |
| Supernus Pharmaceuticals, Inc. | 98.26 Million USD | 334.078% |
| Verastem, Inc. | -83.16 Million USD | -176.567% |
| Waters Corporation | 1.02 Billion USD | 122.5% |
| Vertex Pharmaceuticals Incorporated | 4.6 Billion USD | 104.995% |
| Thermo Fisher Scientific Inc. | 10.8 Billion USD | 102.13% |
| Biogen Inc. | 2.37 Billion USD | 109.676% |
| Viking Therapeutics, Inc. | -100.82 Million USD | -128.123% |
| Perrigo Company plc | 646.2 Million USD | 135.594% |
| Imunon, Inc. | -20.78 Million USD | -1006.76% |
| Esperion Therapeutics, Inc. | -150.1 Million USD | -53.23% |
| Mettler-Toledo International Inc. | 1.16 Billion USD | 119.76% |
| Abeona Therapeutics Inc. | -50.57 Million USD | -354.817% |
| Geron Corporation | -174.78 Million USD | -31.598% |
| Illumina, Inc. | -608 Million USD | 62.169% |
| Homology Medicines, Inc. | -47.75 Million USD | -381.636% |
| Nektar Therapeutics | -243.1 Million USD | 5.387% |
| Unity Biotechnology, Inc. | -37.28 Million USD | -516.93% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.43 Million USD | -417.613% |
| BioMarin Pharmaceutical Inc. | 310.28 Million USD | 174.129% |
| Sangamo Therapeutics, Inc. | -87.42 Million USD | -163.088% |
| Evolus, Inc. | -41.81 Million USD | -450.132% |
| Regeneron Pharmaceuticals, Inc. | 4.65 Billion USD | 104.942% |
| FibroGen, Inc. | -261.4 Million USD | 12.01% |
| Agilent Technologies, Inc. | 1.67 Billion USD | 113.716% |
| OPKO Health, Inc. | -65.51 Million USD | -251.075% |
| Alnylam Pharmaceuticals, Inc. | -228.12 Million USD | -0.828% |
| Exelixis, Inc. | 196.6 Million USD | 216.993% |
| Anavex Life Sciences Corp. | -55.75 Million USD | -312.53% |
| Intellia Therapeutics, Inc. | -506.31 Million USD | 54.572% |
| Zoetis Inc. | 3.68 Billion USD | 106.242% |
| Axsome Therapeutics, Inc. | -224.99 Million USD | -2.231% |
| Kala Pharmaceuticals, Inc. | -36.08 Million USD | -537.465% |
| Corcept Therapeutics Incorporated | 108.32 Million USD | 312.335% |
| Halozyme Therapeutics, Inc. | 451.94 Million USD | 150.893% |
| Insmed Incorporated | -654.73 Million USD | 64.87% |
| TG Therapeutics, Inc. | 26.1 Million USD | 981.264% |
| Incyte Corporation | 919.42 Million USD | 125.017% |
| Emergent BioSolutions Inc. | -505.29 Million USD | 54.481% |